Skip to main content
Article
Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination
Dermatology
  • Stefanie Altmann, HCA Healthcare
  • Dominique Jacobs
  • Thomas M Brown, Jr, HCA Healthcare
  • Preetha Kamath, HCA Healthcare
  • Karthik Krishnamurthy, HCA Healthcare
Division
South Atlantic
Hospital
Orange Park Medical Center
Document Type
Case Report
Publication Date
5-1-2022
Keywords
  • Pemphigoid,
  • Bullous Pemphigoid,
  • BP,
  • COVID-19 vaccine adverse effects,
  • SARS-CoV-2,
  • COVID-19,
  • Moderna COVID-19 mRNA vaccine,
  • autoimmune bullous disease,
  • anti-laminin gamma-1 (p200) pemphigoid,
  • p200 pemphigoid
Abstract

As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely unique, and further investigation into this pathophysiology is warranted.

Publisher or Conference
Skin: The Journal of Cutaneous Medicine
Citation Information
Altmann S, Jacobs D, Brown T, Kamath P, Krishnamurthy K. Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination. SKIN. 2022;6(3):238-242. doi:10.25251/skin.6.3.10